Payments For Asset Acquisitions

No definition available.

Name:	gild_PaymentsForAssetAcquisitions
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Potential Future Milestone Payments, Maximum

+ References

No definition available.

+ Details

Name:	gild_PotentialFutureMilestonePaymentsMaximum
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue, Performance Obligation, Percentage Of U.S. Profits

+ References

No definition available.

+ Details

Name:	gild_RevenuePerformanceObligationPercentageOfUSProfits
Namespace Prefix:	gild_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Name:	us-gaap_NonoperatingIncomeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585

+ Details

Name:	us-gaap_PaymentsToAcquireEquitySecuritiesFvNi
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcellxIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_GlobalStrategicCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=gild_ArcellxIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details) - USD ($) $ in Millions			3 Months Ended
	Feb. 22, 2023	Jan. 30, 2023	Mar. 31, 2023	Mar. 31, 2022	Jun. 19, 2020
Business Combination, Separately Recognized Transactions [Line Items]
Acquired in-process research and development expenses			$ 481	$ 8
Other income (expense), net			(174)	$ (111)
Arcellx, Inc \| Global Strategic Collaboration Agreement
Business Combination, Separately Recognized Transactions [Line Items]
Acquired in-process research and development expenses		$ 212
Maximum potential future milestone payments		835
Payments to acquire equity securities		$ 115
Revenue, performance obligation, percentage of U.S. profits		50.00%
Arcellx, Inc \| Global Strategic Collaboration Agreement \| Arcellx, Inc
Business Combination, Separately Recognized Transactions [Line Items]
Revenue, performance obligation, percentage of U.S. profits		50.00%
Pionyr Immunotherapeutics Inc
Business Combination, Separately Recognized Transactions [Line Items]
Ownership percentage					49.90%
Estimated fair value					$ 70
Other income (expense), net			70
Tmunity Therapeutics
Business Combination, Separately Recognized Transactions [Line Items]
Cash consideration	$ 300
Acquired in-process research and development expenses			244
Maximum potential future milestone payments			$ 1,000